Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10778361 | 0.72 | LMNA (0.30) | LMNACYP2C9 | |
| SCHEMBL17048814 | 0.71 | — | — | |
| SCHEMBL616425 | 0.71 | TP53 (0.32) | LMNACYP2C9MAPT | |
| SCHEMBL8344752 | 0.67 | SMN1; SMN2 (0.35) | LMNACYP2C9MAPT | |
| SCHEMBL9754962 | 0.67 | MAPT (0.36) | LMNACYP2C9MAPT | |
| SCHEMBL20797183 | 0.67 | — | — | |
| SCHEMBL2706623 | 0.65 | SMN1; SMN2 (0.38) | LMNAMAPT | |
| SCHEMBL2691041 | 0.65 | — | — | |
| SCHEMBL14016355 | 0.65 | SMN1; SMN2 (0.38) | LMNAMAPT | |
| SCHEMBL4859696 | 0.65 | KDM4E (0.39) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709719-A1 | 5-CYANO-1H-IMIDAZOLE-2-CARBOXAMIDE COMPOUNDS AS CSF1R INHIBITORS | Modulo Bio, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024254440-A1 | 5-CYANO-1H-IMIDAZOLE-2-CARBOXAMIDE COMPOUNDS AS CSF1R INHIBITORS | MODULO BIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-9394289-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| EP-2016070-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-13 | — | — | EP | disclosed |
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-25 | — | — | US | disclosed |
| US-8859602-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| EP-2016070-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007124319-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | LMNA 3217/4885CYP2C9 1815/4885MAPT 75/4885 |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | LMNA 3217/4885CYP2C9 1815/4885MAPT 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.